Urology equipment manufacturer Direx Medical Systems is planning to enter the MR market withMarex, a low-field magnet shown for the first time at this month'sEuropean Congress of Radiology meeting in Vienna. Marex is a 0.1-tesla permanent magnet
Urology equipment manufacturer Direx Medical Systems is planning to enter the MR market withMarex, a low-field magnet shown for the first time at this month'sEuropean Congress of Radiology meeting in Vienna.
Marex is a 0.1-tesla permanent magnet vertical-field systemwhose appearance bears a passing resemblance to Toshiba's 0.064-teslaAccess magnet. Direx is positioning the system as a low-cost scannerfor the private clinic market in Western countries as well asa secondary unit for public-sector hospitals. The system is alsowell suited for markets in developing countries, according toRon Shifron, director of marketing for Direx, which is based inPetah-Tikva, Israel.
Marex is capable of imaging about 85% of the body and employs10-mtesla/meter gradients. It weighs 2.5 tons, sites in 16 squaremeters and requires neither floor reinforcement nor special magneticshielding. Its power consumption is low enough to enable the useof a regular wall outlet. The scanner also features a detachabletable, which enables users to prepare one patient while anotheris being imaged.
Direx believes there is room in the market for a system likeMarex despite the global plunge in MRI sales. High-field systemshave been most affected by the dropping market, according to Shifron.
"We feel that in this niche market there is still roomfor this kind of machine," Shifron said. "The impressionI'm getting from this meeting is that the low-field market iscoming up and about, even within Europe, where they have had aproblem recognizing the low-field scanners due to all the governmentregulations."
Direx plans to sell Marex for about $400,000 to $500,000 andwill market the system directly where possible through its networkof 10 offices worldwide, with agents responsible for other markets.Direx is in the process of applying for regulatory clearancesto sell the system.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.